Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/h3kg2231

HYPERTENSION MANAGEMENT STRATEGIES: COMPARING PHARMACOLOGICAL AND LIFESTYLE INTERVENTIONS

Mainak Ranjan Baksi[1], Santanu Mandal[2], Abhishek Mondal[3], Rohitaswa Mandal[4*], Sohom Ghosh[5]

[1]Assistant Professor, JIMSH, BudgeBudge, Email ID - mainakbaksi@gmail.com
[2]Assistant Professor, JIMSH, BudgeBudge, Email ID - drsantanumandal2004@gmail.com
[3]Assistant Professor, JIMSH, BudgeBude, Email ID - abhi.jag2006@gmail.com
[4*]Assistant Professor, JIMSH, BudgeBudge Email ID - rohitaswamandal@gmail.com
[5]Assistant Professor, Jims Budge Budge Email ID - sohom.ghosh143@gmail.com

***Corresponding Author:** Rohitaswa Mandal
[*]Assistant Professor, JIMSH, BudgeBudge Email ID - rohitaswamandal@gmail.com

ABSTRACT

Hypertension is a worldwide health issue that causes significant cardiovascular morbidity and mortality. Although drug therapy is the mainline treatment, lifestyle modification has come to be seen as an effective non-pharmacological intervention. The current study contrasts the efficacy, safety, and compliance with pharmacological and lifestyle interventions in the management of primary hypertension. Two hundred persons with Stage 1–2 primary hypertension participated in a twelve-month prospective, parallel-group study. Either the pharmacologic treatment group, which received hypertension drugs as advised by guidelines, or the lifestyle intervention group, which received a structured program that included stress management, weight loss, exercise, and nutritional changes, was allocated at random to the participants. The primary outcomes were decreases in the mean systolic and diastolic blood pressure. Adherence, adverse events, lipid profile, fasting glucose, and body mass index changes were examined via secondary outcomes. 192 participants finished the study. Pharmacologic treatment had a larger decrease in systolic (18.4 mmHg) and diastolic (11.2 mmHg) pressures compared with lifestyle intervention (14.6 mmHg and 9.1 mmHg, respectively; $p < 0.05$). Lifestyle change improved Body Mass Index BMI, High-Density Lipoprotein HDL cholesterol, and fasting glucose significantly, with no adverse effects reported. Compliance was better in the pharmacologic group (88%) than in the lifestyle group (82%). Subgroup analysis identified younger patients and those with dyslipidemia who benefited more from lifestyle interventions, and older patients who needed pharmacological treatment. While both therapies can lower blood pressure, lifestyle changes offer additional metabolic benefits without causing negative side effects. The best way to reduce hypertension is to use both techniques together.

Keywords: Hypertension, Pharmacological Therapy, Lifestyle Interventions, Blood Pressure Control, Cardiovascular Risk

INTRODUCTION

Over one billion people worldwide suffer from hypertension, also known as the "silent killer," which continues to be one of the most frequent chronic illnesses (Schutte et al., 2023). Ischemic heart disease is one of the primary causes of cardiovascular morbidity and mortality stroke, renal failure, is

hypertension (Arima et al., 2011). According to WHO estimates, hypertension accounts for over 13% of all fatalities worldwide and is a significant risk factor for early mortality. Its impact is particularly great in low- and middle-income nations, where the effects are made worse by delayed diagnosis and restricted access to care. Because controlled blood pressure significantly lowers the risk of cardiovascular events, effective management of hypertension is essential (Mills et al., 2020). Pharmacotherapy, which includes Angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, and calcium channel blockers, has been the mainstay of conventional treatment approaches. These medications are successful in controlling blood pressure and its consequences (Mohan et al., 2009).

Lifestyle modifications such as dietary changes, exercise, weight loss, and stress reduction have emerged as non-drug-based strategies to improve cardiovascular health and blood pressure control, even though relying solely on drugs has disadvantages in the form of side effects, expense, and long-term compliance (Lenz et al., 2008). These also have the added benefit of improving glucose metabolism and lipid profiles, among other things, in addition to controlling hypertension (Elmer et al., 2006).

Despite improvements in antihypertensive medication therapy, population blood pressure control rates remain below ideal levels (Choudhry et al., 2022). A significant portion of individuals either have adverse effects that require stopping therapy or fail to reach desired blood pressure levels. Furthermore, the cost of long-term medication is unnecessarily high in settings with limited resources (Burnier et al., 2019). Despite being highly recommended in guidelines, lifestyle treatment is nevertheless underutilized and poorly adhered to due to behavioral and socioeconomic problems (Armario et al., 2013).

The information that is now available, despite the fact that both pharmaceutical and lifestyle techniques have been thoroughly studied, is often fragmentary and focuses on individual components rather than providing a comprehensive picture of the long-term consequences, safety, and efficacy of a direct comparison between them (Caligiuri et al., 2017). Variable results result from the majority of clinical practice's absence of a clear program that combines the two approaches. Therefore, these two therapies must be compared in a single comparative framework so that doctors may use the data to guide individualized hypertension treatment (Carey et al., 2022). Knowing whether a strategy offers greater advantages or whether a combination is the most effective is crucial for improving public health outcomes (Hutton et al., 2013).

Pharmacological therapy has been the mainstay of treatment for hypertension, but it has evolved throughout the years. Antihypertensive medications have been demonstrated to be successful in lowering cardiovascular risk in clinical trials such as ALLHAT and ASCOT. But in other patient groups, negative side effects like weariness, electrolyte imbalances, and a lower quality of life frequently offset these benefits (Hedayati et al., 2011). However, lifestyle modifications have been recognized as important preventative interventions since the Framingham Heart Study. Blood pressure is dramatically reduced by limiting salt intake and increasing intake of fruits, vegetables, and low-fat dairy products, according to the DASH experiment (Timsina et al., 2023). Furthermore, regular aerobic activity, weight loss, and stress reduction can significantly lower blood pressure and enhance cardiovascular health in general. For moderate hypertension, meta-analyses indicate that non-pharmacological therapies can lower systolic pressure by 4–10 mmHg, which is comparable to the impact of a single medication (Maniero et al., 2023). However, the effectiveness of these therapies may be unpredictable if patient compliance declines. Furthermore, not many studies have consistently compared the two approaches in the same cohort (Noone et al., 2018). Previous research has tended to examine lifestyle and pharmaceutical therapies independently, which has hindered our ability to determine their relative effectiveness and transferability to a wide variety of patients.

There is a significant data vacuum regarding the head-to-head comparative efficacy of lifestyle and pharmaceutical therapies, despite the fact that both have been thoroughly studied. Without taking into consideration each component's independent influence, the majority of research either evaluates a single technique or looks at many ways (Cox et al., 2015). Furthermore, when comparing these therapies side by side, there is a dearth of information on long-term outcomes, including metabolic

change, a decrease in cardiovascular events, and patient compliance (Signorovitch et al., 2010). Patient-centered outcomes, such as quality of life and patient satisfaction, are rarely included in research, especially when it comes to chronic diseases. Comparative studies seldom look at sociodemographic factors, including age, comorbidity status, and socioeconomic background, that may affect the results of interventions (Anker et al., 2014). Therefore, there is a lack of sophisticated and reliable comparison data that might aid in the creation of accurate therapeutic guidelines based on real patient profiles for appropriate therapy techniques.

This study compares and assesses the long-term effects, safety, and efficacy of lifestyle changes and medication in the treatment of hypertension. It examines secondary outcomes such as changes in fasting plasma glucose, lipid profile, and body mass index, as well as the degree of blood pressure reduction achieved by both strategies over 12 months. Furthermore, adherence rates and the frequency of adverse events are analyzed for both groups. It also examines subgroup differences like age and comorbid status to identify factors associated with treatment efficacy. By accomplishing these goals, the study offers information to assist doctors in selecting the most effective, patient-centered strategy for treating hypertension.

MATERIALS AND METHODS

Study Design

A tertiary care teaching hospital conducted a prospective, parallel-group comparison research over 12 months. The individuals who were diagnosed with primary hypertension were assigned at random to either the lifestyle intervention or the pharmaceutical treatment group. The pharmacologic group received standard antihypertensive medications with dosage adjustments as necessary, whereas the lifestyle group participated in a monitored non-pharmacologic program that included stress management, weight loss, physical activity, and dietary modifications. The primary objective was to evaluate and contrast the effectiveness of these two strategies in decreasing blood pressure over the long term and improving cardiovascular event outcomes in hypertensive patients.

Study Population

200 patients were gathered with Stage 1 or Stage 2 hypertension, aged 30-65, from outpatient clinics using simple random selection. The American Heart Association's definition of essential hypertension, the absence of prior antihypertensive medication treatment or the completion of a washout period, and the capacity to give written informed consent with follow-up compliance were among the requirements for inclusion. Secondary hypertension, pregnancy, lactation, non-adherence during screening, and the presence of serious comorbidities such as advanced cardiac or renal illness were also excluded. A sufficient representative sample was guaranteed by these stringent exclusion criteria to assess the efficacy of both therapies.

Interventions

Pharmacological Group

Each participant in this group was provided antihypertensive medications by a physician in the form of thiazide diuretics, calcium channel blockers, or angiotensin-converting enzyme inhibitors. During follow-ups, the dosage was adjusted to achieve the desired blood pressure.

Lifestyle Intervention Group

Individualized weight loss plans for patients who were overweight, a low-sodium DASH diet, at least 150 minutes of aerobic exercise per week, and twice-weekly guided yoga and mindfulness classes to reduce stress were all part of the comprehensive lifestyle program given to patients assigned to this group. Antihypertensive drugs were only taken when prescribed by a doctor.

Data Collection and Measurements

The lipid profile, body mass index, fasting plasma glucose levels, and demographic data made up the baseline measurements. A calibrated aneroid sphygmomanometer was used to measure the systolic

and diastolic blood pressure three times every visit, after five minutes of rest, and average the results. Measurement variability was decreased thanks to standardized circumstances. The same parameters were reevaluated after 1, 3, 6, and 12 months of follow-up. Throughout the trial period, the evaluation made sure that results in both intervention groups were regularly monitored.

Outcome Measures

The primary result was a 12-month average drop in both systolic and diastolic blood pressure when compared to baseline levels. Changes in body mass index, fasting glucose, serum lipid levels, adherence to treatments, and the incidence of any negative effects were the secondary outcomes. A thorough assessment of the safety and effectiveness of pharmaceutical and lifestyle therapies in the treatment of hypertension was made possible by the monitoring of these variables.

Statistical Analysis

SPSS version 22.0 was used to analyze the statistics. The independent samples t-test was used to compare continuous data, which were provided as mean ± standard deviation. The Chi-square test was used to examine categorical data, including adherence rates and side effects. A statistically significant result was defined as a p-value of less than 0.05. The differences between the two treatment arms may be appropriately interpreted thanks to this strict statistical approach.

Ethical Considerations

The Institutional Ethics Committee granted ethical approval before the start of the investigation. All of the subjects provided written informed consent. The study was conducted by the Declaration of Helsinki, and participant confidentiality was strictly maintained. At any time, participants might leave the study without it having an impact on their clinical care.

RESULTS

Participant Characteristics

Eight patients were lost to follow-up due to relocation or withdrawal of consent, whereas 192 of the 200 recruited patients (96 in each group) completed the research. There were no statistically significant variations between the two groups' baseline data, including age, gender distribution, body mass index, and first blood pressure readings ($p > 0.05$). The average age of the participants was 49.6 ± 8.2 years, and 54% of them were men. The research population was homogeneous since the incidence of comorbidities such as prediabetes and dyslipidemia was similar in the two groups. In terms of age, sex distribution, BMI, and baseline blood pressure, Table 1 demonstrates that the two groups were similar at baseline. For an objective comparison of treatments, a balanced population is confirmed by the lack of significant differences ($p > 0.05$).

Table 1. Baseline Characteristics of Participants

Characteristics	Pharmacological Group (n=96)	Lifestyle Group (n=96)	p-value
Age (years)	49.4 ± 8.2	49.8 ± 8.3	0.78
Male (%)	55%	53%	0.84
BMI (kg/m²)	28.3 ± 3.2	28.1 ± 3.4	0.67
Systolic BP (mmHg)	152.6 ± 9.3	153.2 ± 9.5	0.56
Diastolic BP (mmHg)	94.1 ± 6.8	94.6 ± 7.1	0.59
Dyslipidemia (%)	42%	44%	0.71
Prediabetes (%)	28%	30%	0.64

Pharmacologic Interventions

The pharmaceutical group's systolic and diastolic blood pressure significantly decreased at the 12-month follow-up. The mean diastolic and systolic pressures decreased by 11.2 and 18.4 mmHg, respectively, from baseline ($p < 0.001$). The fact that lipid and glucose indicators barely altered suggests that the drug's primary effect was on blood pressure control. Although they did not

necessitate stopping treatment, adverse effects, which included moderate dizziness and occasional tiredness, occurred in 12% of patients. A substantial percentage of individuals (88%), continuously taking their medications as directed, adhered to their recommended regimen. With strong adherence (88%), Table 2 shows that pharmaceutical treatment led to a significant drop in both systolic and diastolic blood pressure. However, 12% of patients had modest drug-related side effects, and lipid and glucose alterations were negligible.

Table 2. Outcomes of Pharmacological Interventions

Outcome	Value
Systolic BP Reduction (mmHg)	18.4 ± 4.2
Diastolic BP Reduction (mmHg)	11.2 ± 3.5
Lipid Change (%)	6%
Fasting Glucose Change (mg/dL)	2.0 ± 1.1
Adherence (%)	88%
Adverse Events (%)	12%

Lifestyle Interventions

Significant drops in blood pressure were also observed in the group that underwent lifestyle intervention; after 12 months, the systolic and diastolic pressures were 14.6 mmHg and 9.1 mmHg, respectively ($p < 0.001$). Furthermore, this group's metabolic indicators showed notable improvements, including a mean BMI drop of 2.3 kg/m2, an improvement in HDL cholesterol, and slight variations in fasting glucose. Adverse effects were limited, and quality of life was reported to have improved. Because respondents had trouble adhering to their exercise and food regimens over time, adherence was slightly lower (82%) than expected. Although not as much as pharmaceutical therapy, Table 3 shows that lifestyle changes also considerably decreased blood pressure. Notably, this group showed no adverse effects and showed larger improvements in glucose metabolism, HDL levels, and BMI.

Table 3. Outcomes of Lifestyle Interventions

Outcome	Value
Systolic BP Reduction (mmHg)	14.6 ± 4.7
Diastolic BP Reduction (mmHg)	9.1 ± 3.2
BMI Reduction (kg/m²)	2.3 ± 0.6
Improved HDL (%)	18%
Fasting Glucose Reduction (mg/dL)	6.0 ± 1.5
Adherence (%)	82%
Adverse Events (%)	0%

Comparative Analysis

Short-term vs. Long-term Effectiveness

In the first three months, both treatments significantly lowered blood pressure, but in the early follow-ups, the medication group saw faster control. Despite a decline in the group difference after 12 months, the pharmacologic therapy remained statistically significant ($p = 0.04$).

Safety, Side Effects, and Adherence

The lifestyle group had no adverse events due to the intervention, while the pharmaceutical group had more medication-related side effects, but these were usually moderate. Adherence was slightly lower for those using numerous medications, although it was higher for those taking medicine. Behavior weariness caused a gradual decline in lifestyle adherence. When comparing the two approaches, Table 4 reveals statistically significant differences that favor pharmaceutical therapy for lowering blood pressure. The benefit of changing one's lifestyle, however, was that there were no

negative consequences. In the lifestyle group, adherence was somewhat lower but not substantially different.

Table 4. Comparative Analysis of Interventions

Parameter	Pharmacological	Lifestyle	p-value
Systolic BP Reduction (mmHg)	18.4	14.6	0.04*
Diastolic BP Reduction (mmHg)	11.2	9.1	0.05
Adherence (%)	88	82	0.18
Adverse Events (%)	12	0	0.01*



Figure 1. Comparison of Blood Pressure Reduction

Figure 1 compares the mean decreases in systolic and diastolic blood pressure over 12 months between the pharmaceutical and lifestyle intervention groups. Compared to lifestyle changes, pharmacological treatment produced a larger decrease in both measures.

Subgroup Analyses

Age-stratified analysis revealed that older individuals benefited more from pharmacologic therapy, whereas younger participants (less than 50 years old) in the lifestyle group saw greater drops in blood pressure. With a lifestyle change, patients with concurrent dyslipidemia showed better metabolic responses. Socioeconomic factors had an impact on adherence; those with greater health literacy and access to formal counselling programs had better adherence. Table 5 shows that while older patients had better control with pharmaceutical therapy, younger patients (less than 50 years old) and those with dyslipidemia benefitted more from lifestyle modifications. Both treatments produced comparable outcomes in participants without dyslipidemia.

Table 5. Subgroup Analysis Findings

Subgroup	Better Response	Notes
Age <50 years	Lifestyle Intervention	Greater BP reduction with lifestyle
Age ≥50 years	Pharmacological Therapy	Greater BP control with drugs
With Dyslipidemia	Lifestyle Intervention	Improved metabolic outcomes
Without Dyslipidemia	Both Similar	Minimal difference observed



Figure 2: Metabolic and BMI Improvements

Figure 2 compares the improvements in BMI and metabolism between pharmaceutical treatment and lifestyle modifications. Compared to medication therapy, lifestyle changes led to a higher decrease in BMI, higher HDL values, and better fasting glucose.

DISCUSSION

The experiment demonstrates the equivalent effectiveness of lifestyle modification and medication in lowering blood pressure in patients with primary hypertension. Because pharmacologic therapy acts quickly, there is a more noticeable reduction in both systolic and diastolic blood pressure, particularly in the first few months. Lifestyle changes significantly enhance metabolic markers, including body mass index, HDL cholesterol, and fasting glucose level, even if they only marginally reduce blood pressure (Xiao et al., 2020). Long-term compliance hinders lifestyle change, although pharmaceutical compliance is higher. Interestingly, there are no negative occurrences in the lifestyle group, but 12% of patients receiving medication had moderate side effects (Lien et al., 2007).

Various modes of action can account for these variations among therapies. Pharmacological drugs directly affect vascular resistance and fluid status, which causes blood pressure to drop more quickly (Marques-Vidal et al., 2020). Lifestyle changes, however, are ineffective in addressing underlying metabolic disorders (Chen et al., 2022). By improving metabolic health, reducing body weight, and improving endothelial function, lifestyle changes have a progressive effect. In addition to controlling hypertension, they may also lower the risk of diabetes and dyslipidemia (Nicolson et al., 2004). The absence of adverse effects strengthens their standing as a long-term, safe treatment. However, the little decline in adherence over time might be explained by the fact that lifestyle modifications necessitate long-lasting behavioral change. The results suggest that a combination of the two methods may yield the greatest outcomes (Pritchet et al., 2005).

The study's strengths include a prospective design, comparable participant groups, and intensive follow-up over 12 months increases the validity of the results. The assessment of many outcomes, including blood pressure, metabolism, adherence, and adverse events, offers a thorough picture of the intervention's effects (Pladevall et al., 2010). Moreover, subgroup analysis aids in customized therapy by identifying how age and comorbidities impact treatment results. Nonetheless, it's critical to recognize certain boundaries (Tsioufis et al., 2020). Because the study is being conducted in a particular place, its generalizability may be restricted. Adherence evaluation is prone to bias as it partially relies on self-reporting. Also excluded are individuals on combo therapy, which limits the interpretation of synergistic effects (Roy et al., 2017).

Public health and clinical practice will be significantly impacted by the findings. Pharmacologic therapy is essential, particularly for elderly patients or those in urgent need of blood pressure

management (Appel et al., 2006). However, the significant metabolic benefit and safety record of lifestyle modifications suggest that they are an essential first-line or adjuvant strategy. In order to improve compliance, clinicians should emphasize behavioral support and patient education in addition to medication therapy and rigorous lifestyle modifications (Ribeiro et al., 2023). Creating conditions that encourage stress management, physical exercise, and a balanced diet must be the goal of public health initiatives. Reducing drug dependence and healthcare costs may be possible if lifestyle changes are included in national guidelines for hypertension (Lenz et al., 2008).
The long-term cardiovascular consequences of these therapies, as well as their implications on the incidence of myocardial infarction and stroke, should be evaluated by further study. Research should also look at combination tactics and figure out how best to combine lifestyle and medication interventions. Results from large multicentre trials that examine a diverse population would also be more broadly applicable in a range of cultural and socioeconomic contexts. Future research must examine novel approaches, including community-based and technology-based treatments, to improve adherence to lifestyle modifications. Finally, research that includes patient-reported outcomes will give a more comprehensive picture of the improvements in quality of life associated with each intervention (Cakir et al., 2006).

This study emphasizes how medication therapy and lifestyle modifications may be used in tandem to manage hypertension. Drugs promise rapid management, while lifestyle changes offer comprehensive health benefits without side effects and are more effective for long-term illness prevention. The results support a shift toward more integrated care models that combine organized lifestyle treatments with medical treatment. The findings encourage policymakers to fund preventative measures that can reduce the burden of hypertension and related cardiovascular disease, such as community well-being initiatives and public health promotion. In terms of clinical practice, the study supports a patient-centered approach that customizes therapies to fit each person's requirements, preferences, and risk characteristics.

CONCLUSION

This investigation demonstrates that although both pharmaceutical treatment and lifestyle modifications are useful strategies for treating primary hypertension, the clinical significance and scope of their effects differ. Pharmaceutical treatment considerably and more quickly lowers both systolic and diastolic blood pressure, confirming its use as a first-line treatment to provide prompt management. Despite these benefits, a small percentage of patients have modest side effects; for this reason, it is impossible to overlook the need for tailored medication selection and closer monitoring. However, changing one's lifestyle can have a positive impact on one's body mass index, lipid profile, and glucose metabolism, regardless of how well it lowers blood pressure. These findings provide credence to the notion that lifestyle modifications are advantageous for overall cardiovascular health and do not have any negative side effects, in addition to helping control blood pressure. The subgroup analysis also shows that patient characteristics have an impact on the intervention's results. While older patients benefit more from pharmaceutical intervention, younger patients and those with dyslipidemia respond better to lifestyle changes. All of these results support the necessity of treating hypertension with a patient-centered approach that adapts treatment plans to each patient's unique profile rather than employing a standard method. Promoting coordinated lifestyle programs would, from a public health perspective, lower the prevalence of comorbidities associated with hypertension and save the healthcare system money. Standard care should include lifestyle counselling, and patient education and community reinforcement should be used to ensure long-term compliance. In order to determine if multi-component methods have any causal influence on the prevention of cardiovascular events, more research should evaluate these strategies with longer follow-up periods. Lastly, this study emphasizes that the best way to treat hypertension is not to choose one intervention over another, but rather to combine medication therapy with lifestyle modifications for long-term control and improved patient outcomes.

REFERENCES

1. Anker, S. D., Agewall, S., Borggrefe, M., Calvert, M., Jaime Caro, J., Cowie, M. R., ... & Kirchhof, P. (2014). The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. *European heart journal*, *35*(30), 2001-2009.
2. Appel, L. J., Brands, M. W., Daniels, S. R., Karanja, N., Elmer, P. J., & Sacks, F. M. (2006). Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension*, *47*(2), 296-308.
3. Arima, H., Barzi, F., & Chalmers, J. (2011). Mortality patterns in hypertension. *Journal of hypertension*, *29*, S3-S7.
4. Armario, P., & Waeber, B. (2013). Therapeutic strategies to improve control of hypertension. *Journal of hypertension*, *31*, S9-S12.
5. Burnier, M., & Egan, B. M. (2019). Adherence in hypertension: a review of prevalence, risk factors, impact, and management. *Circulation research*, *124*(7), 1124-1140.
6. Cakir, H., & Pinar, R. (2006). Randomized controlled trial on lifestyle modification in hypertensive patients. *Western journal of nursing research*, *28*(2), 190-209.
7. Caligiuri, S. P., & Pierce, G. N. (2017). A review of the relative efficacy of dietary, nutritional supplements, lifestyle, and drug therapies in the management of hypertension. *Critical reviews in food science and nutrition*, *57*(16), 3508-3527.
8. Carey, R. M., Moran, A. E., & Whelton, P. K. (2022). Treatment of hypertension: a review. *Jama*, *328*(18), 1849-1861.
9. Chen, Y., Yuan, J., Lei, X., Cheng, Y., & Wei, X. (2022). Metabolic status and vascular endothelial structure in obese hypertensive patients treated with non-pharmacological therapies: A systematic review and meta-analysis. *Plos one*, *17*(12), e0279582.
10. Choudhry, N. K., Kronish, I. M., Vongpatanasin, W., Ferdinand, K. C., Pavlik, V. N., Egan, B. M., ... & American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. (2022). Medication adherence and blood pressure control: a scientific statement from the American Heart Association. *Hypertension*, *79*(1), e1-e14.
11. Cox, J. L., & Pieper, K. (2015). Harnessing the power of real-life data. *European Heart Journal Supplements*, *17*(suppl_D), D9-D14.
12. Elmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., ... & PREMIER Collaborative Research Group. (2006). Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. *Annals of internal medicine*, *144*(7), 485-495.
13. Hedayati, S. S., Elsayed, E. F., & Reilly, R. F. (2011). Non-pharmacological aspects of blood pressure management: what are the data?. *Kidney international*, *79*(10), 1061-1070.
14. Hutton, B., Tetzlaff, J., Yazdi, F., Thielman, J., Kanji, S., Fergusson, D., ... & Leenen, F. H. (2013). Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses. *Systematic reviews*, *2*(1), 44.
15. Lenz, T. L., & Monaghan, M. S. (2008). Lifestyle modifications for patients with hypertension. *Journal of the American Pharmacists Association*, *48*(4), e92-e102.
16. Lien, L. F., Brown, A. J., Ard, J. D., Loria, C., Erlinger, T. P., Feldstein, A. C., ... & Svetkey, L. P. (2007). Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. *Hypertension*, *50*(4), 609-616.
17. Maniero, C., Lopuszko, A., Papalois, K. B., Gupta, A., Kapil, V., & Khanji, M. Y. (2023). Non-pharmacological factors for hypertension management: a systematic review of international guidelines. *European journal of preventive cardiology*, *30*(1), 17-33.
18. Marques-Vidal, P. (2020). Comparison of lifestyle changes and pharmacological treatment on cardiovascular risk factors. *Heart*, *106*(11), 852-862.
19. Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Nephrology*, *16*(4), 223-237.

20. Mohan, S., & Campbell, N. R. (2009). Hypertension management: Time to shift gears and scale up national efforts. *Hypertension*, *53*(3), 450-451.
21. Nicolson, D. J., Dickinson, H. O., Campbell, F., & Mason, J. M. (2004). Lifestyle interventions or drugs for patients with essential hypertension: a systematic review. *Journal of hypertension*, *22*(11), 2043-2048.
22. Noone, C., Dwyer, C. P., Murphy, J., Newell, J., & Molloy, G. J. (2018). Comparative effectiveness of physical activity interventions and anti-hypertensive pharmacological interventions in reducing blood pressure in people with hypertension: protocol for a systematic review and network meta-analysis. *Systematic reviews*, *7*(1), 128.
23. Pladevall, M., Brotons, C., Gabriel, R., Arnau, A., Suarez, C., de la Figuera, M., ... & Writing Committee on behalf of the COM99 Study Group*. (2010). Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). *Circulation*, *122*(12), 1183-1191.
24. Pritchett, A. M., Foreyt, J. P., & Mann, D. L. (2005). Treatment of the metabolic syndrome: the impact of lifestyle modification. *Current atherosclerosis reports*, *7*(2), 95-102.
25. Ribeiro, F., Teixeira, M., Alves, A. J., Sherwood, A., & Blumenthal, J. A. (2023). Lifestyle medicine as a treatment for resistant hypertension. *Current hypertension reports*, *25*(10), 313-328.
26. Roy, A., Naik, N., & Srinath Reddy, K. (2017). Strengths and limitations of using the polypill in cardiovascular prevention. *Current cardiology reports*, *19*(5), 45.
27. Schutte, A. E., Jafar, T. H., Poulter, N. R., Damasceno, A., Khan, N. A., Nilsson, P. M., ... & Tomaszewski, M. (2023). Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. *Cardiovascular research*, *119*(2), 381-409.
28. Signorovitch, J. E., Wu, E. Q., Yu, A. P., Gerrits, C. M., Kantor, E., Bao, Y., ... & Mulani, P. M. (2010). Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. *Pharmacoeconomics*, *28*(10), 935-945.
29. Timsina, Y. P., Pandey, P., Mondal, I. H., & Dar, A. H. (2023). Non-pharmacological management of hypertension: A systematic review. *Food Chemistry Advances*, *3*, 100406.
30. Tsioufis, K., Kreutz, R., Sykara, G., van Vugt, J., & Hassan, T. (2020). Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. *Journal of hypertension*, *38*(6), 1016-1028.
31. Xiao, J., Ren, W. L., Liang, Y. Y., Shen, H., Gao, Y. X., Chu, M. J., ... & Yu, Y. F. (2020). Effectiveness of lifestyle and drug intervention on hypertensive patients: a randomized community intervention trial in rural China. *Journal of General Internal Medicine*, *35*(12), 3449-3457.